Clinical Study for the Safety and Therapeutic Efficacy of the AI-QMMM Designed TamavaqTM Personalised Vaccine in Patients With Newly Diagnosed Glioma.

Recruiting

Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.

Trial locations(1 site)

Greece

Biogenea Pharmaceuticals Ltd, Thessaloniki